Penn spinout Verismo Therapeutics launched a new Research and Development Center in Philadelphia’s CIC (Cambridge Innovation Center) Labs + Innovation Campus at 3675 Market St.
Verismo plans to use this space for its in-house translational research and to process development work to support the ongoing activities for the clinical trial of its SynKIR-110 therapy, a cell therapy that aims to treat patients with mesothelin-expressing mesotheliomas.
Read more about Verismo’s new space in the following articles: